> > > How it Helps

Effective bleed control for people with acquired hemophilia.

NovoSeven® RT is the only bypassing agent that is approved by the FDA for acquired hemophilia.

> > > How it Helps

Effective bleed control for people with acquired hemophilia.

NovoSeven® RT is the only bypassing agent that is approved by the FDA for acquired hemophilia.

Proven to be effective.

As a first-line treatment, NovoSeven® RT is 92% effective and recommended by an international consensus.

Acquired Hemophilia: NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) was 92% effective as first-line treatment

Lower volume means fast infusion.

Because it's a low-volume treatment, NovoSeven® RT takes 2 to 5 minutes to infuse.a  


aAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.

bBased on the initial dose for a 70-kg patient with acute bleeding.

Established safety profile.

Recombinant manufacturing means NovoSeven® RT is made without any human blood or plasma, which minimizes the possibility of viral contamination. And in a clinical trial, 4% of patients with acquired hemophilia experienced adverse events (blood clots).

Icon: Microscrope

What if I need surgery or a procedure?

We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is effective for preventing bleeds during and after surgery and procedures in people with acquired hemophilia.

Talk to your doctor for more information on the surgical use of NovoSeven® RT.

What about surgery and procedures?

Approved for surgical use and procedures for patients with acquired hemophilia.

Get information on surgery

Young man and boy standing

Hear from people who

share your experience.

Hear patient stories

Illustration: Removing syringe cap

New to treatment? It's

easy to get started.

See the steps

Icon: 5-step purification process of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Recombinant manufacturing

minimizes risk of viral contamination.

Learn about proven safety

Selected Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven® RT?

  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
    • congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
    • history of heart or blood vessel diseases
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information